Literature DB >> 27016890

Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults.

M Monseu1, S Dubois2, J Boursier3, C Aubé4, F Gagnadoux5, G Lefthériotis6, P-H Ducluzeau7.   

Abstract

AIM: This study aimed to determine the association between visceral adipose tissue (VAT), liver fat (LF) content, and other markers of the metabolic syndrome (MetS) and osteoprotegerin (OPG) in dysmetabolic adults.
METHODS: Subjects from the NUMEVOX cohort were included if they fulfilled at least one MetS criterion. They then underwent a thorough metabolic and cardiovascular evaluation, including arterial stiffness, atherosclerotic plaques, homoeostasis model assessment for insulin resistance (HOMA-IR) indices and OPG. VAT and LF content were measured by magnetic resonance imaging (MRI). Ultrasound examination of arteries and arterial stiffness were recorded, and age- and gender-adjusted paired correlations calculated.
RESULTS: Body mass index, waist circumference and MRI-derived VAT correlated with OPG, whereas abdominal subcutaneous fat did not. OPG levels were strongly correlated with LF content (r=0.25, P=0.003), liver markers such as alanine aminotransferase (r=0.39, P<0.001) and HOMA-IR index (r=0.39, P<0.0001). Plasma OPG also correlated with arterial stiffness and the number of atherosclerotic sites.
CONCLUSION: Plasma OPG levels are positively associated with both liver markers and increased LF content, but not with subcutaneous fat in dysmetabolic men. These findings suggest that elevated OPG levels may play a role in the link between fatty liver disease and enhanced cardiovascular risk.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Insulin resistance; Liver steatosis; Metabolic syndrome; Osteoprotegerin; Vascular complications

Mesh:

Substances:

Year:  2016        PMID: 27016890     DOI: 10.1016/j.diabet.2016.02.004

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  9 in total

1.  Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study.

Authors:  Zachary P Fricker; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-23       Impact factor: 11.382

2.  Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker.

Authors:  Saba Tariq; Sundus Tariq; Shaista Hussain; Mukhtiar Baig
Journal:  Pak J Med Sci       Date:  2020 Sep-Oct       Impact factor: 1.088

Review 3.  Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Gian Marco Andreoli; Miriam D'Avanzo; Delia De Mitri; Pasquale Pierimarchi
Journal:  World J Gastroenterol       Date:  2018-05-21       Impact factor: 5.742

4.  Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker.

Authors:  Carmen G Barbu; Andreea L Arsene; Suzana Florea; Alice Albu; Anca Sirbu; Sorina Martin; Alina C Nicolae; George T A Burcea-Dragomiroiu; Daniela E Popa; Bruno S Velescu; Ion B Dumitrescu; Niculina Mitrea; Doina Draganescu; Dumitru Lupuliasa; Demetrios A Spandidos; Aristides M Tsatsakis; Cristina M Dragoi; Simona Fica
Journal:  Mol Med Rep       Date:  2017-08-28       Impact factor: 2.952

5.  ABCC6 deficiency promotes dyslipidemia and atherosclerosis.

Authors:  Christopher Brampton; Viola Pomozi; Li-Hsieh Chen; Ailea Apana; Sara McCurdy; Janna Zoll; William A Boisvert; Gilles Lambert; Daniel Henrion; Simon Blanchard; Sheree Kuo; Georges Leftheriotis; Ludovic Martin; Olivier Le Saux
Journal:  Sci Rep       Date:  2021-02-16       Impact factor: 4.379

6.  Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation.

Authors:  Audrey Laurain; Isabelle Rubera; Micheline Razzouk-Cadet; Stéphanie Bonnafous; Miguel Albuquerque; Valérie Paradis; Stéphanie Patouraux; Christophe Duranton; Olivier Lesaux; Georges Lefthériotis; Albert Tran; Rodolphe Anty; Philippe Gual; Antonio Iannelli; Guillaume Favre
Journal:  Biomedicines       Date:  2022-06-24

7.  The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans.

Authors:  Giuseppe Daniele; Deidre Winnier; Andrea Mari; Jan Bruder; Marcel Fourcaudot; Zuo Pengou; Andrea Hansis-Diarte; Christopher Jenkinson; Devjit Tripathy; Franco Folli
Journal:  Acta Diabetol       Date:  2017-11-18       Impact factor: 4.280

8.  Association of Nonalcoholic Fatty Liver Disease With Osteoporotic Fractures: A Cross-Sectional Retrospective Study of Chinese Individuals.

Authors:  Yanmao Wang; Gen Wen; Runhua Zhou; Wanrun Zhong; Shengdi Lu; Chengfang Hu; Yimin Chai
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-23       Impact factor: 5.555

9.  The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease.

Authors:  Cheng Zhang; Elias Bjornson; Muhammad Arif; Abdellah Tebani; Alen Lovric; Rui Benfeitas; Mehmet Ozcan; Kajetan Juszczak; Woonghee Kim; Jung Tae Kim; Gholamreza Bidkhori; Marcus Ståhlman; Per-Olof Bergh; Martin Adiels; Hasan Turkez; Marja-Riitta Taskinen; Jim Bosley; Hanns-Ulrich Marschall; Jens Nielsen; Mathias Uhlén; Jan Borén; Adil Mardinoglu
Journal:  Mol Syst Biol       Date:  2020-04       Impact factor: 11.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.